MAGNOLIA Trial

Disease State: Marginal zone lymphoma

MAGNOLIA Trial

MAGNOLIA (NCT03846427) is a Phase 2, multicenter, open-label, single-arm trial of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Reading
28 May 2025

BGB-11417-102 (NCT04883957) is a Phase 1 trial of sonrotoclax in adult patients with mature B-cell malignancies.

Reading
6 Dec 2024

BGB-11417-101 (NCT04277637) is a Phase 1a/1b, open-label, dose-escalation and expansion trial of sonrotoclax in patients with mature B-cell malignancies.

Reading
6 Dec 2024

BGB-3111-215 (NCT04116437) is a Phase 2, multicenter, single-arm trial of zanubrutinib in patients with previously treated B-cell lymphoma intolerant of prior treatment with ibrutinib and/or acalabrutinib.

Reading
6 Dec 2024

MAGNOLIA (NCT03846427) is a Phase 2, multicenter, open-label, single-arm trial of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Reading
6 Dec 2024